A neutral, harm-reduction guide to mazdutide, a dual glucagon/GLP-1 agonist approved in China, and what to monitor.
At a glance
Mazdutide is a dual glucagon (GCG) and GLP-1 receptor agonist, structurally an oxyntomodulin analogue, developed by Innovent under license from Eli Lilly for the Chinese market. The GLP-1 arm suppresses appetite and lowers blood sugar, while the glucagon arm can raise energy expenditure and improve hepatic fat metabolism. In June 2025 China's NMPA approved mazdutide for chronic weight management, making it the first approved dual GCG/GLP-1 agonist, and a glycemic-control approval followed later in 2025.
This is an educational tracking guide, not medical advice or a recommendation. Note that mazdutide is approved in China but not in the US or EU.
In the Chinese trials and label, mazdutide is titrated upward over weeks to a maintenance dose to limit GI effects, given once weekly by subcutaneous injection, with a higher-dose option under review for more severe obesity. Doses here reflect the trial and label context only, not a recommendation.
Because the glucagon component can raise energy expenditure, the metabolic profile differs somewhat from pure GLP-1 drugs, but weight loss is still gradual and diet-dependent. Track lean mass indirectly through strength as part of any rapid loss phase.
Mazdutide's approval is specific to China; access elsewhere is off the regulated path. Expect GLP-1 class GI effects and the thyroid tumor signal that governs the class, plus the added consideration that glucagon agonism can affect glucose and heart rate. Use only with medical supervision and monitoring.
Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.